<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10625034</article-id><article-id pub-id-type="pmcid-ver">PMC10625034.1</article-id><article-id pub-id-type="pmcaid">10625034</article-id><article-id pub-id-type="pmcaiid">10625034</article-id><article-id pub-id-type="pmid">37921772</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.41416</article-id><article-id pub-id-type="publisher-id">zld230204</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Substance Use and Addiction</subject></subj-group></article-categories><title-group><article-title>Factors Associated With Abrupt Discontinuation of Long-Term High-Dose Opioid Treatment</article-title><alt-title alt-title-type="headline">Abrupt Discontinuation of Long-Term High-Dose Opioid Treatment</alt-title><alt-title alt-title-type="running-head">Abrupt Discontinuation of Long-Term High-Dose Opioid Treatment</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Vivas-Valencia</surname><given-names initials="C">Carolina</given-names></name><degrees>PhD</degrees><xref rid="zld230204aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="H">Huiru</given-names></name><degrees>PhD</degrees><xref rid="zld230204aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stringfellow</surname><given-names initials="EJ">Erin J.</given-names></name><degrees>PhD</degrees><xref rid="zld230204aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Russell</surname><given-names initials="WA">W. Alton</given-names></name><degrees>PhD</degrees><xref rid="zld230204aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morgan</surname><given-names initials="JR">Jake R.</given-names></name><degrees>PhD</degrees><xref rid="zld230204aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tadrous</surname><given-names initials="M">Mina</given-names></name><degrees>PharmD</degrees><degrees>PhD</degrees><xref rid="zld230204aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jalali</surname><given-names initials="MS">Mohammad S.</given-names></name><degrees>PhD</degrees><xref rid="zld230204aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="zld230204aff1"><label>1</label>Department of Biomedical Engineering and Chemical Engineering, The University of Texas, San Antonio</aff><aff id="zld230204aff2"><label>2</label>Massachusetts General Hospital, Harvard Medical School, Boston</aff><aff id="zld230204aff3"><label>3</label>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada</aff><aff id="zld230204aff4"><label>4</label>Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston</aff><aff id="zld230204aff5"><label>5</label>Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> September 24, 2023.</p><p content-type="published-online"><bold>Published:</bold> November 3, 2023. doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.41416</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2023 Vivas-Valencia C et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zld230204cor1"><bold>Corresponding Author:</bold> Mohammad S. Jalali, PhD, Massachusetts General Hospital Institute for Technology Assessment, 101 Merrimac St, Ste 1010, Room 1032, Boston, MA 02114 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="msjalali@mgh.harvard.edu">msjalali@mgh.harvard.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Vivas-Valencia and Dr Dong had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Vivas-Valencia, Dong, Stringfellow, Morgan, Tadrous, Jalali.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Vivas-Valencia, Dong, Stringfellow, Russell, Morgan, Jalali.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Vivas-Valencia, Dong, Jalali.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> Vivas-Valencia, Dong, Russell, Morgan.</p><p><italic toggle="yes">Obtained funding:</italic> Stringfellow, Jalali.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Stringfellow.</p><p><italic toggle="yes">Supervision:</italic> Jalali.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> Research reported in this study was supported in part by grant U01FD007064 from the US Food and Drug Administration. Dr Dong reported being supported in part by the Canadian Institutes of Health Research Fellowship Award. Dr Morgan reported being supported in part by the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH), grant P30DA040500.</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZLD230204-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p><p><bold>Additional Contributions:</bold> Yuhua Bao, PhD, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, and Benjamin I. Bearnot, MD, Division of General Internal Medicine, Massachusetts General Hospital, Boston, made important contributions to this analysis and provided critical feedback on the report. They were supported in part by grant U01FD007064 from the US Food and Drug Administration.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-11-03T10:00"><day>3</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2023</year></pub-date><volume>6</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">448503</issue-id><elocation-id>e2341416</elocation-id><history><date date-type="received"><day>22</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>24</day><month>9</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>11</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>05</day><month>11</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-26 21:25:18.713"><day>26</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 Vivas-Valencia C et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamanetwopen-e2341416.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamanetwopen-e2341416.pdf">jamanetwopen-e2341416.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.41416"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study investigates factors associated with abrupt discontinuation of long-term high-dose opioid treatment at the national level and across US states.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZLD230204"><title>Introduction</title><p>Managing long-term high-dose (LTHD) opioid regimens is a concern.<sup><xref rid="zld230204r1" ref-type="bibr">1</xref></sup> The repercussions of abrupt discontinuation are profound, encompassing adverse outcomes such as withdrawal, illicit substance use, and mental health complications.<sup><xref rid="zld230204r2" ref-type="bibr">2</xref>,<xref rid="zld230204r3" ref-type="bibr">3</xref></sup> Research shows that a notable majority of patients, exceeding 70% nationwide, encounter abrupt discontinuation of LTHD treatments,<sup><xref rid="zld230204r4" ref-type="bibr">4</xref></sup> which signals potential gaps in management strategies. This study aims to identify factors associated with abrupt discontinuation, extending previous research<sup><xref rid="zld230204r4" ref-type="bibr">4</xref>,<xref rid="zld230204r5" ref-type="bibr">5</xref>,<xref rid="zld230204r6" ref-type="bibr">6</xref></sup> by incorporating more recent data and identifying their associations at the national level and across states.</p></sec><sec id="H1-2-ZLD230204"><title>Methods</title><p>This cohort study followed the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link> reporting guideline and was exempt from review and granted waiver of informed consent by the Mass General Brigham institutional review board because data were not obtained through participant interaction. We analyzed a sample from the IQVIA Longitudinal Prescription database to identify opioid treatment episodes that started in January 2014 or later and had been discontinued by September 2020. We examined all data for the following year (through September 2021) to ensure participants remained continuously enrolled. LTHD episodes were defined as lasting at least 90 days with at least 90 daily morphine milligram equivalents (DMME) for at least 14 consecutive days.<sup><xref rid="zld230204r4" ref-type="bibr">4</xref></sup> Episodes were abruptly discontinued if the final 30 days&#8217; DMME was at least 60 or represented a greater than 35% reduction compared with the previous 30 days (eMethods in <xref rid="note-ZLD230204-1-s" ref-type="supplementary-material">Supplement 1</xref>). Associations between abrupt discontinuation and race and ethnicity, age, sex, payment source, initial opioid dosage (included to control for clinical decisions), and year of discontinuation were analyzed using multivariable logistic regressions at national and state levels. Race and ethnicity data were collected to identify disparities among different races and ethnicities.</p><p>Study design details are available in the eMethods in <xref rid="note-ZLD230204-1-s" ref-type="supplementary-material">Supplement 1</xref>. Statistical analysis was performed using R software version 4.2.0 (R Project for Statistical Computing) from September 2022 to May 2023.</p></sec><sec id="H1-3-ZLD230204"><title>Results</title><p>Among 354&#8201;940 discontinued LTHD episodes, 192&#8201;037 (54.1%) were from female patients; 151&#8201;352 (42.6%) were aged at least 65 years, 135&#8201;784 (38.3%) were aged 50 to 64 years; 46&#8201;332 (13.1%) were Black, 24&#8201;535 (6.9%) were Hispanic, and 284&#8201;073 (80.0%) were White. During the study period, 247&#8201;308 (69.7%) of discontinued episodes were abruptly discontinued. Nationally, abrupt discontinuation was positively associated with being male, Black, Hispanic, or aged at least 50 years; having Medicare, private insurance, or being cash-paying; and starting with DMME greater than or equal to 50. The rate of abrupt discontinuation also decreased between 2014 and 2019 (<xref rid="zld230204t1" ref-type="table">Table</xref>).</p><table-wrap position="float" id="zld230204t1" orientation="portrait"><label>Table. </label><caption><title>Patient Characteristics and Associations With Abrupt Discontinuation of Long-Term High-Dose Opioid Treatment Episodes, Stratified by Episode Discontinuation Type at the National Level</title></caption><table frame="hsides" rules="groups"><col width="17.72%" span="1"/><col width="16.69%" span="1"/><col width="16.67%" span="1"/><col width="15.65%" span="1"/><col width="16.69%" span="1"/><col width="16.58%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Variables</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Odds ratio (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Discontinued LTHD episodes (N&#8201;=&#8201;354&#8201;940)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Abruptly discontinued episodes (n&#8201;=&#8201;247&#8201;308)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Gradually discontinued (n&#8201;=&#8201;107&#8201;632)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Unadjusted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Adjusted</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">192&#8201;037 (54.1)</td><td valign="top" align="left" rowspan="1" colspan="1">132&#8201;050 (53.4)</td><td valign="top" align="left" rowspan="1" colspan="1">59&#8201;987 (55.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">162&#8201;903 (45.9)</td><td valign="top" align="left" rowspan="1" colspan="1">115&#8201;258 (46.6)</td><td valign="top" align="left" rowspan="1" colspan="1">47&#8201;645 (44.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1.09 (1.08-1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">1.09 (1.08-1.11)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 18-34</td><td valign="top" align="left" rowspan="1" colspan="1">9964 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">6677 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3287 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 35-49</td><td valign="top" align="left" rowspan="1" colspan="1">57&#8201;840 (16.3)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;475 (16.0)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;365 (17.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.05 (1.01-1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">1.04 (0.99-1.09)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 50-64</td><td valign="top" align="left" rowspan="1" colspan="1">135&#8201;784 (38.3)</td><td valign="top" align="left" rowspan="1" colspan="1">94&#8201;163 (38.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41&#8201;621 (38.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1.11 (1.06-1.16)</td><td valign="top" align="left" rowspan="1" colspan="1">1.08 (1.03-1.13)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;65</td><td valign="top" align="left" rowspan="1" colspan="1">151&#8201;352 (42.6)</td><td valign="top" align="left" rowspan="1" colspan="1">106&#8201;993 (43.3)</td><td valign="top" align="left" rowspan="1" colspan="1">44&#8201;359 (41.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.18 (1.13-1.23)</td><td valign="top" align="left" rowspan="1" colspan="1">1.16 (1.11-1.22)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race and ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td><td valign="top" align="left" rowspan="1" colspan="1">46&#8201;332 (13.1)</td><td valign="top" align="left" rowspan="1" colspan="1">32&#8201;827 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;505 (12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.07 (1.04-1.09)</td><td valign="top" align="left" rowspan="1" colspan="1">1.08 (1.06-1.11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">24&#8201;535 (6.9)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;243 (7.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7292 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.04 (1.01-1.07)</td><td valign="top" align="left" rowspan="1" colspan="1">1.06 (1.03-1.09)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td><td valign="top" align="left" rowspan="1" colspan="1">284&#8201;073 (80.0)</td><td valign="top" align="left" rowspan="1" colspan="1">197&#8201;238 (79.8)</td><td valign="top" align="left" rowspan="1" colspan="1">86&#8201;835 (80.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Payment</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicaid</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;304 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6883 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3421 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare</td><td valign="top" align="left" rowspan="1" colspan="1">135&#8201;758 (38.2)</td><td valign="top" align="left" rowspan="1" colspan="1">95&#8201;854 (38.8)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;904 (37.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.19 (1.14-1.24)</td><td valign="top" align="left" rowspan="1" colspan="1">1.11 (1.06-1.16)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Private insurance</td><td valign="top" align="left" rowspan="1" colspan="1">188&#8201;967 (53.2)</td><td valign="top" align="left" rowspan="1" colspan="1">129&#8201;569 (52.4)</td><td valign="top" align="left" rowspan="1" colspan="1">59&#8201;398 (55.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.08 (1.03-1.13)</td><td valign="top" align="left" rowspan="1" colspan="1">1.06 (1.02-1.11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cash</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;911 (5.6)</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;002 (6.1)</td><td valign="top" align="left" rowspan="1" colspan="1">4909 (4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.52 (1.44-1.60)</td><td valign="top" align="left" rowspan="1" colspan="1">1.40 (1.33-1.48)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Initial DMME level</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;50</td><td valign="top" align="left" rowspan="1" colspan="1">97&#8201;396 (27.4)</td><td valign="top" align="left" rowspan="1" colspan="1">57&#8201;877 (23.4)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;519 (36.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 50-90</td><td valign="top" align="left" rowspan="1" colspan="1">141&#8201;794 (39.9)</td><td valign="top" align="left" rowspan="1" colspan="1">109&#8201;857 (44.4)</td><td valign="top" align="left" rowspan="1" colspan="1">31&#8201;937 (29.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1.34 (1.31-1.37)</td><td valign="top" align="left" rowspan="1" colspan="1">1.33 (1.31-1.36)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 90-120</td><td valign="top" align="left" rowspan="1" colspan="1">59&#8201;788 (16.8)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;639 (16.0)</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;149 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1.70 (1.66-1.73)</td><td valign="top" align="left" rowspan="1" colspan="1">1.68 (1.64-1.72)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;120</td><td valign="top" align="left" rowspan="1" colspan="1">55&#8201;962 (15.8)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;935 (16.1)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;027 (14.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2.34 (2.30-2.39)</td><td valign="top" align="left" rowspan="1" colspan="1">2.30 (2.26-2.34)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Year of discontinuation</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Per year increase</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">0.94 (0.93-0.94)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.94-0.95)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: DMME, daily morphine milligram equivalents; LTHD, long-term high-dose; NA, not applicable.</p></table-wrap-foot></table-wrap><p>In 9 states, Black patients had a higher likelihood of abrupt discontinuation than White patients, and a lower risk in 1 state (<xref rid="zld230204f1" ref-type="fig">Figure</xref>); Hispanic patients had a higher risk in 2 states. Abrupt discontinuation was more likely among male patients in 12 states (<xref rid="zld230204f1" ref-type="fig">Figure</xref>). Compared with Medicaid enrollees, cash payers faced a higher risk in 6 states. In only 1 state were patients with private insurance at higher risk, whereas Medicare patients were at higher risk in 2 states. Starting with DMME greater than or equal to 120 was associated with increased risk of abrupt discontinuation in 48 states and the District of Columbia. Twenty-nine states had a decrease over time in abrupt discontinuations.</p><fig position="float" id="zld230204f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Factors Associated With Abrupt Discontinuation of Long-Term High-Dose Opioid Treatment Episodes at the State Level</title><p>Variables were not included in the state-level models if any categories had low prevalence due to small sample sizes. Other statistically significant results not presented in the figure include Arizona and New York (Hispanic patients); California and South Carolina (aged 50-64 years); California, Colorado, Idaho, Indiana, Nebraska, Ohio, and South Carolina (aged 65 years or older); Alaska, California, Delaware, Florida, Michigan, and Tennessee (cash insurance); Alaska (private insurance); and Alaska and Arizona (Medicare payment). For DMMEs, 50 to 90 was significant in 32 states, 90 to 120 was significant in 35 states, and 120 or greater was significant 49 states. aOR indicates adjusted odds ratio; NA, not applicable.</p><p><sup>a</sup>Significant result after Benjamini&#8211;Hochberg correction for multiple comparisons.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e2341416-g001.jpg"/></fig></sec><sec id="H1-4-ZLD230204"><title>Discussion</title><p>Our national-level cohort study identified a significant risk of abrupt discontinuation, with the associated sociodemographic factors consistent with prior research.<sup><xref rid="zld230204r4" ref-type="bibr">4</xref></sup> We also found that abrupt discontinuation occurred less frequently over time, suggesting that clinicians have responded to concerns about the risks associated with this practice. Additionally, our study found large heterogeneities across states, which were distinct from the national-level results. At the state level, sociodemographic factors most often associated with abrupt discontinuation were being male and a Black patient.</p><p>A limitation of our study is the lack of data on rationale for dosage adjustments, treatment discontinuation, and information on patient behavior, especially whether having received guidance from the physician on tapering within the last high-dosage prescription. However, we would not expect Black or male patients to consistently have conditions or practices that would make abrupt discontinuation more appropriate for them than for White or female patients. Thus, it is likely our findings point to real disparities. Further analysis should investigate the reasons for the disparities and why they exist in some states but not others.</p></sec></body><back><ref-list id="REF-ZLD230204"><title>References</title><ref id="zld230204r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Baldini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Von Korff</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>EHB</given-names></string-name></person-group>. <article-title>A review of potential adverse effects of long-term opioid therapy: a practitioner&#8217;s guide</article-title>. <source>Prim Care Companion CNS Disord</source>. <year>2012</year>;<volume>14</volume>(<issue>3</issue>):<elocation-id>PCC.11m01326</elocation-id>. doi:<pub-id pub-id-type="doi">10.4088/PCC.11m01326</pub-id><pub-id pub-id-type="pmid">23106029</pub-id><pub-id pub-id-type="pmcid">PMC3466038</pub-id></mixed-citation></ref><ref id="zld230204r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Oliva</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Bowe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation</article-title>. <source>BMJ</source>. <year>2020</year>;<volume>368</volume>:<fpage>m283</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.m283</pub-id><pub-id pub-id-type="pmid">32131996</pub-id><pub-id pub-id-type="pmcid">PMC7249243</pub-id></mixed-citation></ref><ref id="zld230204r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Binswanger</surname><given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Glanz</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Faul</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>The association between opioid discontinuation and heroin use: a nested case-control study</article-title>. <source>Drug Alcohol Depend</source>. <year>2020</year>;<volume>217</volume>:<elocation-id>108248</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108248</pub-id><pub-id pub-id-type="pmid">32927194</pub-id><pub-id pub-id-type="pmcid">PMC10959283</pub-id></mixed-citation></ref><ref id="zld230204r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Sherry</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Neill</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Sorbero</surname><given-names>M</given-names></string-name></person-group>. <article-title>Rapid discontinuation of chronic, high-dose opioid treatment for pain: prevalence and associated factors</article-title>. <source>J Gen Intern Med</source>. <year>2022</year>;<volume>37</volume>(<issue>7</issue>):<fpage>1603</fpage>-<lpage>1609</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-021-07119-3</pub-id><pub-id pub-id-type="pmid">34608565</pub-id><pub-id pub-id-type="pmcid">PMC9130349</pub-id></mixed-citation></ref><ref id="zld230204r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Witkin</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>MC</given-names></string-name></person-group>. <article-title>Abrupt discontinuation of long-term opioid therapies among privately insured or Medicare Advantage adults, 2011-2017</article-title>. <source>Pain Med</source>. <year>2021</year>;<volume>22</volume>(<issue>7</issue>):<fpage>1702</fpage>-<lpage>1704</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnaa350</pub-id><pub-id pub-id-type="pmid">33155020</pub-id><pub-id pub-id-type="pmcid">PMC8311577</pub-id></mixed-citation></ref><ref id="zld230204r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Neprash</surname><given-names>HT</given-names></string-name>, <string-name name-style="western"><surname>Gaye</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name></person-group>. <article-title>Abrupt discontinuation of long-term opioid therapy among Medicare beneficiaries, 2012-2017</article-title>. <source>J Gen Intern Med</source>. <year>2021</year>;<volume>36</volume>(<issue>6</issue>):<fpage>1576</fpage>-<lpage>1583</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-020-06402-z</pub-id><pub-id pub-id-type="pmid">33515197</pub-id><pub-id pub-id-type="pmcid">PMC8175547</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZLD230204-1"><supplementary-material id="note-ZLD230204-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eMethods. </bold>Supplemental Methods</p><p>
eReferences
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2341416-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2341416-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>